Tegaserod: withdrawal from the world market. A treatment for constipation with cardiovascular adverse effects.
D002318:Cardiovascular Diseases / Q000139:chemically induced*; D003248:Constipation / Q000188:drug therapy; D017277:Drug Approval; D064420:Drug-Related Side Effects and Adverse Reactions; D019981:Health Care Sector; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use
D007211:Indoles